A range of topics were covered:
- Inherent particle challenges with biologic drugs and cell therapy products
- Safety impact of particles
- Regulatory perspectives
- Testing perspectives for biologic drugs
- Mitigation of particles during manufacturing
- Control measures for packaging components
- Particle formation during fill/finish
- Risk-based approaches to visible particle inspection
Key take-aways were noted:
- USP is planning to create a Chapter specific to a standard for particles in packaging components and administration systems.
- NIST has completed the next generation of standards for protein particle testing (based upon abraded ETFE) – scheduled to be available in Fall-2017.
- Upstream controls are extremely important – explaining why there is such a focus on mitigating particles on packaging components and other upstream processes that lead to the completed filled biologic drug (which is visually inspected at 100%).
- Silicone oil use continues to be an area requiring better understanding, investigation, and control.
- In respect to the biologic drug itself, 2-10 micron particles are important to understand, however the technology is still not strong in being able to accurately quantify particles at this size.
The issue of particles is challenging; clearly needed is a cross-industry approach, comprising industry, academia, regulators, and suppliers, to consider life-cycle management and improve clarity. West remains at the forefront of particle technology – active in organizations addressing them, and developing new methods to measure them – always with the focus of patient safety. To read more on particle technology visit West's Knowledge Center on our website.